| Comparison 1. Single IV agents compared for pulmonary exacerbations with P aeruginosa | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Single IV agents | Single IV agents | |||||
| [ceftazidime versus aztreonam] FEV1 (absolute change) litres Follow-up: 2 weeks | The mean absolute change in FEV1 litres in the IV aztreonam group ranged between 0.27 and 0.54 | The mean absolute change in FEV1 litres in the IV ceftazidime group was 0.06 lower (0.44 lower to 0.32 higher) | 46 (Elborn 1992, Salh 1992) | ⊕⊕⊝⊝ low1,2 | ||
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; FEV1: forced expiratory volume in 1 second; MD: mean difference
The quality of the evidence was downgraded by 1 as 4 participants received both drugs in Salh 1992 study,
The quality of the evidence was downgraded by 1 due to serious heterogeneity (chi-squared p<0.1, I-squared inconsistency statistic of 50%-74.99%)
From: 9, Pulmonary monitoring, assessment and management
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.